Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis-Reference-Cited by-同舟云学术

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis

Published:2015-09-26 Issue:43 Volume:7 Page:69412-69419
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Vincenzi Bruno¹,Nannini Margherita²,Fumagalli Elena³,Bronte Giuseppe⁴,Frezza Anna Maria¹,De Lisi Delia¹,Ceruso Mariella Spalato¹,Santini Daniele¹,Badalamenti Giuseppe⁴,Pantaleo Maria Abbondanza²,Russo Antonio⁴,Tos Angelo Paolo Dei⁵,Casali Paolo³,Tonini Giuseppe¹

Affiliation:

1. Department of Oncology, University Campus Bio-Medico, Rome, Italy

2. Department of Specialized, Experimental and Diagnostic Medicine, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

3. Adult Mesenchymal Tumor Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

4. Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

5. Department of Oncology and Pathology, General Hospital of Treviso, Treviso, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to Chen, A.; Zhang, X. Comment on “Golčić et al. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. Cancers 2023, 15, 4081”;Cancers;2023-11-28

2. Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors – a real-world multi-center study;Translational Oncology;2023-04

3. 2023 GEIS Guidelines for gastrointestinal stromal tumors;Therapeutic Advances in Medical Oncology;2023-01

4. Safety, efficacy, and selection strategy of laparoscopic local gastrectomy for gastrointestinal stromal tumors in the esophagogastric junction;Frontiers in Surgery;2022-09-27

5. Treatment of Gastrointestinal Stromal Tumors (GISTs): A Focus on Younger Patients;Cancers;2022-06-08